A novel mechanism for anti‐EGFR antibody action involves chemokine‐mediated leukocyte infiltration
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Overexpression of the epidermal growth factor receptor (EGFR) is a hallmark of squamous cell carcinoma of the head and neck (SCCHN). Monoclonal antibodies (mAbs) against EGFR are currently used for therapy of recurrent or metastatic disease; however, their mode of action is not completely understood. To investigate the immunological effects of anti‐EGFR mAb, we generated a three‐dimensional spheroid model of EGFR‐expressing SCCHN and used this model to study the effect of anti‐EGFR mAb on leukocyte migration toward tumors. Pretreatment with the blocking anti‐EGFR mAb EMD 72000, its F(ab′)2 fragments or an EGFR tyrosine kinase inhibitor led to substantially increased leukocyte infiltration into EGFR overexpressing tumor spheroids, but not into those with low EGFR expression. Nonblocking anti‐EGFR mAb or fibroblast‐specific mAb did not affect leukocyte infiltration, suggesting that the observed increase in leukocyte infiltration depends on interference with EGFR activation. Using a human cytokine macroarray, we demonstrated that the blockade of EGFR by anti‐EGFR mAb in EGFR‐overexpressing SCCHN cells leads to differential expression of several cytokines and chemokines, including the chemokine MCP‐1/CCL‐2. The significant upregulation of MCP‐1/CCL2 on exposure to anti‐EGFR mAb was confirmed by quantitative PCR and enzyme‐linked immunospot analyses. Moreover, blocking anti‐MCP‐1 antibody inhibited leukocyte migration toward tumor cells induced by anti‐EGFR mAb, pointing to an important role of MCP‐1/CCL2 in anti‐EGFR mAb‐induced leukocyte migration. Our findings demonstrate that anti‐EGFR mAb induces leukocyte infiltration to tumor spheroids by upregulating chemokine expression. This novel mechanism for anti‐EGFR mAb action may contribute to the antitumor effects of anti‐EGFR mAb in vivo. © 2009 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Specific Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase
Fry, D. W., Kraker, A. J., McMichael, A., Ambroso, L. A., Nelson, J. M., Leopold, W. R., Connors, R. W., & Bridges, A. J. (1994) · Science · doi:10.1126/science.8066447 · Cited by 806 · cited 1×
“PD 153035 (ParkeDavis, Pfizer, Karlsruhe, Germany) is a specific inhibitor of the EGFR tyrosine kinase.(23,24)”
Background
Cited by
Multicellular tumor spheroids: An underestimated tool is catching up again
Hirschhaeuser, F., Menne, H., Dittfeld, C., West, J., Mueller-Klieser, W., & Kunz-Schughart, L. A. (2010) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2010.01.012 · Cited by 1,674
In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform
Katt, M. E., Placone, A. L., Wong, A. D., Xu, Z. S., & Searson, P. C. (2016) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2016.00012 · Cited by 754
“Tumor spheroids are also being used to develop therapeutic strategies to stimulate an immune response by promoting infiltration and cytotoxicity of various immune cells (Durek et al., 1999; Hoffmann et al., 2009).”
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids
Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0833 · Cited by 594
Matrigel: From discovery and ECM mimicry to assays and models for cancer research
Benton, G., Arnaoutova, I., George, J., Kleinman, H. K., & Koblinski, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.06.005 · Cited by 477
Van den Eynde, M., Mlecnik, B., Bindea, G., Fredriksen, T., Church, S. E., Lafontaine, L., Haicheur, N., Marliot, F., Angelova, M., Vasaturo, A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.003 · Cited by 281
Metadata
- Authors
- Hoffmann, T. K., Schirlau, K., Sonkoly, E., Brandau, S., Lang, S., Pivarcsi, A., Balz, V., Müller, A., Homey, B., Boelke, E., Reichert, T., Friebe‐Hoffmann, U., Greve, J., Schuler, P., Scheckenbach, K., Schipper, J., Bas, M., Whiteside, T. L., & Bier, H.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2009-03-25
- Volume
- 124
- Issue
- 11
- Pages
- 2589-2596
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2032015913
- Cited by
- 63
- References
- 1
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A novel mechanism for anti‐EGFR antibody action involves chemokine‐mediated leukocyte infiltration. https://app.cochat.ai/papers/10.1002/ijc.24269
- The paper
- Hoffmann, T. K., Schirlau, K., Sonkoly, E., Brandau, S., Lang, S., Pivarcsi, A., Balz, V., Müller, A., Homey, B., Boelke, E., Reichert, T., Friebe‐Hoffmann, U., Greve, J., Schuler, P., Scheckenbach, K., Schipper, J., Bas, M., Whiteside, T. L., & Bier, H. (2009). A novel mechanism for anti‐EGFR antibody action involves chemokine‐mediated leukocyte infiltration. International Journal of Cancer. https://doi.org/10.1002/ijc.24269
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.